Yeah, it's a double edged sword. One one side, it's great to have a CEO can market the company. But on the other, I agree that investors making decisions based on what Wayne said or the website may tend to downplay the risk involved. This is not only an early stage company (in the TAVR business), although with some revenue, but one that depends on successfully completing clinical trials to succeed. So that's double the risk.
I have a science background with a geology degree and years spent working as a lab tech in chemistry labs but I'm not a biologist or doctor so I struggle with comprehending medical studies and data releases and really have to work hard to try to put it all together to make investment decisions.
AVR Price at posting:
$26.15 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)